Rituximab
- CAS No.
- 174722-31-7
- Chemical Name:
- Rituximab
- Synonyms
- Retuxin;Rituxan;Mabthera;Mab thera;Hsdb 7455;Rituximab;Unii-4F4X42syq6;Immunoglobulin G1;Rituximab 13mg/ml;Rituximab USP/EP/BP
- CBNumber:
- CB01074099
- Molecular Formula:
- C6416H9874N1688O1987S44
- Molecular Weight:
- 0
- MOL File:
- Mol file
- Modify Date:
- 2024/7/2 8:54:55
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|---|---|
| Signal word | Warning |
| Hazard statements | H372 |
| Precautionary statements | P260-P264-P270-P314-P501 |
Rituximab Chemical Properties,Uses,Production
Description
Rituximab, a chimeric murine/human monoclonal antibody approved in the United States only for treating refractory or relapsed B-cell lymphomas, reacts with the CD20 antigen. It contains the complementarity determining murine anti-CD20 antibody 2B8 regions in conjunction with human kappa and IgG1 heavy-chain constant region sequences. The vector was cloned into Chinese hamster ovarian cells as the production source of immunoglobulin. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids with a molecular weight of 145 kD. Rituximab has a binding affinity for the CD20 antigen of approximately 8.0 nM, similar to the parent murine antibody, 2B8[1].
Uses
Rituximab is being used for Coronavirus-related infections.
brand name
Rituxan (IDEC).
Mechanism of action
Rituximab has a unique mode of action and can induce the killing of CD20+ cells via multiple mechanisms. The direct effects of rituximab include complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity, and the indirect effects include structural changes, apoptosis, and sensitization of cancer cells to chemotherapy.
Clinical Use
Rituximab has seen use in transplant patients in several settings: (1) treatment of post-transplant lymphoproliferative disease (PTLD); (2) prevention of rejection; (3) ABO-incompatible transplantation; (4) treatment of rejection; (5) desensitization in HLA sensitized patients. The treatment of post-transplant lymphoproliferative disease has probably seen the greatest use of rituximab with great success. However, there is no formal indication of this use. In non-transplant patients with lymphoma, rituximab is typically combined with other chemotherapeutic agents with somewhat worse results.
Rituximab Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| Shanghai Minbiotech Co., Ltd. | +8617315815539 | CHINA | 129 | 58 | Inquiry |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | China | 21668 | 55 | Inquiry |
| career henan chemical co | +86-0371-86658258 +8613203830695 | China | 29825 | 58 | Inquiry |
| Hubei Ipure Biology Co., Ltd | +8613367258412 | China | 10326 | 58 | Inquiry |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | China | 24330 | 58 | Inquiry |
| AFINE CHEMICALS LIMITED | +86-0571-85134551 | China | 15395 | 58 | Inquiry |
| Wuhan Fortuna Chemical Co., Ltd | +86-027-59207850 | China | 5989 | 58 | Inquiry |
| Baoji Guokang Healthchem co.,ltd | +8615604608665 15604608665 | CHINA | 9427 | 58 | Inquiry |
| Nantong HI-FUTURE Biology Co., Ltd. | +undefined18051384581 | China | 3136 | 58 | Inquiry |
Related articles
- The Comprehensive Guide to Rituximab: Mechanisms, Applications, and Care
- Rituximab, a pioneering chimeric monoclonal antibody, has been a beacon of hope in the realms of oncology and immunology.
- Apr 12，2024
- Several mechanisms of action of rituximab
- Rituximab has become a mainstay in treating a broad variety of B-cell malignancies.
- Apr 10，2024
- Rituximab—The World"s First Oncology Monoclonal Antibody Therapy
- Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmun....
- Jan 29，2023
174722-31-7(Rituximab)Related Search:
1of4
chevron_right